Reset Pharma will use PEX010 in a Phase II clinical trial. Credit: Maxim Shmelyev/Shutterstock.com.

Reset Pharmaceuticals has entered a licensing agreement with Filament Health for psilocybin drug PEX010 for treating demoralisation syndrome.

The agreement grants Reset Pharma a licence to use PEX010 in a Phase II clinical trial approved by the US Food and Drug Administration (FDA).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Filament will license its proprietary PEX010 and associated intellectual property to Reset Pharma.

The botanical drug candidate is formulated as a capsule for oral administration. It is also being assessed in several Phase I and II human clinical trials approved by the FDA and Health Canada.

Reset Pharma co-founder and interim CEO Jan-Anders Karlsson stated: “Clinical trial data indicates that psilocybin may be effective in treating demoralisation syndrome, so we are pleased to partner with Filament, a leader in the development of pharmaceutical-grade botanical psilocybin, to advance our clinical trial.

“Reset Pharma’s lead programme focuses on developing a psilocybin-related product to treat demoralisation syndrome in patients with cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe that these patients have significant levels of demoralisation with a perceived lack of control, hopelessness and helplessness and an increased risk of suicide, and currently have no effective treatment options.”

In August 2023, Filament Health received FDA approval for initiating two clinical trials at American research institutions.

These trials are intended to study the effects of PEX010 in patients with mental health conditions including cancer-related anxiety and depression.